Gilead's HIV drug Descovy wins China's endorsement; Revance investors smile as frown lines drug succeeds pivotal studies
→ Around the same time controversial Chinese scientist Jiankui He was working CRISPR tools to edit embryos that were later born as twin girls — in what critics deemed a misguided effort to stem the growing threat of HIV in China — China’s health regulator was likely reviewing Gilead’s TAF-based HIV drug $GILD, Descovy, which was granted approval on Tuesday. The drug, which was approved in the United States and Europe in 2016, joins Gilead’s TAF-based Genvoya as an approved treatment for HIV in China, where the number of HIV diagnoses have risen significantly in recent years, in part due to expanded screening. The Chinese government has provided free antiretroviral treatment to all persons living with HIV since 2003, Gilead noted in its release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
